CompoAtlas

Herbesan Gorge et Bronches

Food supplement declared in France, declaration No 2022-7-1063

Herbesan Gorge et Bronches (Herbesan) is a food supplement declared in France. Status: withdrawal from the market announced for 1 July 2028. None of the rules we check flags an issue with its declared composition; vitamin and mineral doses are not published by Compl'Alim and are therefore not checked.

Brand
Herbesan
Food business operator placing the product on the market
LABORATOIRES SUPER DIET
Status
Withdrawal from the market announced for 1 July 2028
Form
Bottle
Daily dose
6 cuillères à café
Directions for use
1 à 2 cuillères à café 3 fois par jour
Intended populations
Children aged 4 to 10, Adolescents aged 11 to 17, Men, Women
Not recommended (according to the manufacturer)
Breastfeeding women, Pregnant women, Infants (under 1 year), Children (under 6)
Objectives stated by the manufacturer (these are not authorised claims)
Respiratory tract, Immunity

Declaration 235123, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.

Declared composition

Plants

PlantPartPreparationPer day
Plantago lanceolata L.FeuilleExtrait sec aqueux4,800 mg
Plantago lanceolata L.FeuilleExtrait fluide aqueux1,200 mg
Citrus limon (L.) Burm. f.Essence (épicarpe, zeste)Pression à froid45 mg

Other active ingredients

NamePer day
mielnot declared
miel de Manukanot declared
Propolisnot declared

Vitamins and minerals

Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).

Declared formNutrientEFSA limit, adults Maximum dose in France
CholécalciférolVitamine D100 µg (4,000 UI)5 µg (200 UI)
Bisglycinate de zincZinc25 mg15 mg

Additives

E330, E415, E202

Other ingredients

Eau purifiée

The evidence date of this ingredient list is unknown.

Has the product changed? Photograph the packaging.

Label warnings

Autre consommations déconseillées : Déconseillé en cas d'asthme ou d'allergies, notamment aux produits de la ruche.Autres mises en garde et avertissements : Surveillez la pression artérielle chez les personnes hypertendues. Ne pas utiliser avant exposition au soleil. Prendre l’attache d’un professionnel de santé avant tout usage.

Regulatory points

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Propolis
    Read the warning, when it applies and the studies cited

    PROPOLIS - Oral

    Cautions and warnings

    Condition of application: All uses.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are allergic to bee products, poplar tree products, or balsam of Peru (Brinker 2010; Marcucci 1995; Valsecchi and Cainelli 1984; Melli et al. 1983; Rudzki and Gryzwa 1983).

    Sources cited by Health Canada (5)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Marcucci MC. Propolis: chemical composition, biological properties and therapeutic activity. Apidologie 1995;26:83-89.
    • Melli MC, Giorgini S, Sertoli A. Occupational dermatitis in a bee-keeper. Contact Dermatitis 1983;9(5):427-428. PubMed Case report
    • Rudzki E, Grzywa Z. Dermatitis from propolis. Contact Dermatitis 1983;9(1):40-45. PubMed
    • Valsecchi R, Cainelli T. Dermatitis from propolis. Contact Dermatitis 1984;11(5):317. PubMed

    Condition of application: Relief of sore throat/mouth and throat infections.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (PPRC 2020; Scully 2006; Hsu et al. 2004; Teraki and Shiohara 2001; Machácková 1988; Hausen et al. 1987; Valsecchi and Cainelli 1984; Melli et al. 1983; Rudzki and Grzywa 1983).

    Sources cited by Health Canada (9)
    • Hausen BM, Wollenweber E, Senff H, Post B. Propolis allergy (II): the sensitizing properties of 1,1-dimethylallyl caffeic acid ester. Contact Dermatitis 1987;17:171-177. PubMed Case report
    • Hsu CY, Chiang WC, Weng TI, Chen WJ, Yuan A. Laryngeal edema and anaphalactic shock after topical propolis use for acute pharyngitis. American Journal of Emergency Medicine 2004;22(5):432-433. PubMed Case report
    • Machackova J. The incidence of allergy to propolis in 605 consecutive patients patch tested in Prague. Contact Dermatitis 1988;18:210-212. PubMed
    • Melli MC, Giorgini S, Sertoli A. Occupational dermatitis in a bee-keeper. Contact Dermatitis 1983;9(5):427-428. PubMed Case report
    • PPRC 2020: Pharmacopoeia of the People's Republic of China, Volume 1, English edition. Beijing (CN): The State Pharmacopoeia Commission of the People's Republic of China; 2020.
    • Rudzki E, Grzywa Z. Dermatitis from propolis. Contact Dermatitis 1983;9(1):40-45. PubMed
    • Scully C. Propolis: A background (Letter). British Dental Journal 2006;200(7):359-360. PubMed
    • Teraki Y, Shiohara T. Propolis-induced granulomatous contact dermatitis accompanied by marked lymphadenopathy. British Journal of Dermatology 2001;144:1277-1278. PubMed Case report
    • Valsecchi R, Cainelli T. Dermatitis from propolis. Contact Dermatitis 1984;11(5):317. PubMed

    Health Canada monograph dated 30 May 2025

    PROPOLIS Buccal

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are allergic to bee products, poplar tree products, or balsam of Peru (Brinker 2010; Marcucci 1995; Valsecchi and Cainelli 1984; Melli et al. 1983; Rudzki and Gryzwa 1983).

    Sources cited by Health Canada (5)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Marcucci MC. Propolis: chemical composition, biological properties and therapeutic activity. Apidologie 1995;26:83-89.
    • Melli MC, Giorgini S, Sertoli A. Occupational dermatitis in a bee-keeper. Contact Dermatitis 1983;9(5):427-428. PubMed Case report
    • Rudzki E, Grzywa Z. Dermatitis from propolis. Contact Dermatitis 1983;9(1):40-45. PubMed
    • Valsecchi R, Cainelli T. Dermatitis from propolis. Contact Dermatitis 1984;11(5):317. PubMed

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Condition of application: All products, except those not swallowed (e.g., gargles, rinses).

    Ask a health care practitioner/health care provider/health care professional/doctor/ physician before use if you are pregnant or breastfeeding.

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (PPRC 2020; Scully 2006; Hsu et al. 2004; Teraki and Shiohara 2001; Machácková 1988; Hausen et al. 1987; Valsecchi and Cainelli 1984; Melli et al. 1983; Rudzki and Grzywa 1983).

    Sources cited by Health Canada (8)
    • Hausen BM, Wollenweber E, Senff H, Post B. Propolis allergy (II): the sensitizing properties of 1,1-dimethylallyl caffeic acid ester. Contact Dermatitis 1987;17:171-177. PubMed Case report
    • Hsu CY, Chiang WC, Weng TI, Chen WJ, Yuan A. Laryngeal edema and anaphalactic shock after topical propolis use for acute pharyngitis. American Journal of Emergency Medicine 2004;22(5):432-433. PubMed Case report
    • Melli MC, Giorgini S, Sertoli A. Occupational dermatitis in a bee-keeper. Contact Dermatitis 1983;9(5):427-428. PubMed Case report
    • PPRC 2020: Pharmacopoeia of the People’s Republic of China, Volume 1, English edition. Beijing (CN): The State Pharmacopoeia Commission of the People’s Republic of China; 2020.
    • Rudzki E, Grzywa Z. Dermatitis from propolis. Contact Dermatitis 1983;9(1):40-45. PubMed
    • Scully C. Propolis: A background (Letter). British Dental Journal 2006;200(7):359-360. PubMed
    • Teraki Y, Shiohara T. Propolis-induced granulomatous contact dermatitis accompanied by marked lymphadenopathy. British Journal of Dermatology 2001;144:1277-1278. PubMed Case report
    • Valsecchi R, Cainelli T. Dermatitis from propolis. Contact Dermatitis 1984;11(5):317. PubMed

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 29 May 2026

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Brand : Herbesan

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Enter to analyse, Shift+Enter for a new line